Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2712374 | 0.96 | PARP1 (0.47) | PARP1ADORA1ATICMAP4K4VNN1 | |
| SCHEMBL2712751 | 0.89 | MRGPRX4 (0.49) | PARP1ADORA1MAP4K4VNN1 | |
| SCHEMBL2710646 | 0.84 | PARP1 (0.45) | PARP1ADORA1VNN1FYN | |
| SCHEMBL2710917 | 0.82 | MYC (0.47) | PARP1ADORA1ATICPARP2MYC | |
| SCHEMBL2713727 | 0.80 | MRGPRX4 (0.49) | PARP1ADORA1MAP4K4 | |
| SCHEMBL3859503 | 0.76 | GSK3B (0.50) | ATICVNN1KDM1AAR | |
| SCHEMBL3721296 | 0.76 | KAT6A (0.56) | PARP1ATICPARP2EGLN2MYC | |
| SCHEMBL2726368 | 0.75 | MYC (0.45) | PARP1ADORA1ATICPARP2MYC | |
| SCHEMBL8956752 | 0.74 | PARP2 (0.55) | PARP1MAP4K4PARP2EGLN2MYC | |
| SCHEMBL2711241 | 0.73 | MRGPRX4 (0.54) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630144-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-07 | — | — | EP | disclosed |
| EP-2630144-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270868-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | PARP1 1134/4885ADORA1 1786/4885ATIC 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.